9WM
TGTX icon

9258 Wealth Management’s TG Therapeutics TGTX Stock Holding History

9258 Wealth Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-11,000
Closed -$122K – 320
2019
Q4 		$122K Buy
+11,000
New +$83.6K 0.04% 299

Other funds holding TGTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

9258 Wealth Management's TGTX Position: Q1 2020 in Review

9258 Wealth Management sold out of TG Therapeutics (TGTX) in Q1 2020, closing a stake of 11,000 shares — an estimated $122K sold.

9258 Wealth Management first reported a position in TGTX in Q4 2019 and held it in 1 quarter. The position peaked at $122K in Q4 2019. 146 funds tracked by Wall St. Rank hold TGTX as of Q1 2020.

  • 9258 Wealth Management reported no remaining TG Therapeutics position as of Q1 2020 after selling out during the quarter.
  • 9258 Wealth Management sold 11,000 TG Therapeutics shares in Q1 2020, an estimated $122K.
  • 9258 Wealth Management first reported a position in TG Therapeutics in Q4 2019 and held it in 1 quarter.
  • 9258 Wealth Management's TG Therapeutics position peaked at $122K in Q4 2019.
  • 146 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2020.

Based on 9258 Wealth Management's 13F filing for Q1 2020, filed 5 May 2020.